本帖最后由 雪山飞狐 于 2009-10-12 08:14 编辑
Stemedica国际公司总部在瑞士洛桑，Stemedica细胞技术公司是它的子公司，总部设在美国加利福尼亚州圣迭戈，是一家专业生物制药公司，致力于开发和生产成体干细胞技术和产品，针对RP的技术是把干细胞分化培养成视网膜色素上皮细胞和干细胞因子，然后移植给患者。
2009.7.1公布了初步的临床前实验结果（动物实验），为期18个月的实验是在俄罗斯的费奥多罗夫眼科研究所使用Stemedica专有的多细胞的技术，成体干细胞和干细胞因子。这项研究结果将提交给在2009年9月30号纽约召开的视网膜国际会议。
1. The study showed a statistically significant gain (77%) in the treated eye (with RPE cells) over the control eye of the same animal. ， However, both the treated eye and the control eye were approximately 10 times more active (response to ERG) compared to non-treated (normally dystrophic) control animal.
2. The RPE and NSC cells were effective in preserving the thickness of the outer nuclei layer of the retina.
3. A contra lateral effect was observed between the test and control eyes. As a result, both eyes exhibited significant improvement。 It is believed that the positive outcome in the control eye was achieved through the systemic release of cytokines; growth and other important factors; peptides; and, molecules from stem cells transplanted into the treated eye. This phenomenon is referred to by Stemedica as “The Factor Release Effect” and branded by the company as StemedicaFRE™。 These factors, circulating in the blood flow, effect and mobilize endogenous stem cells. StemedicaStemedica believes improvement in the contra lateral eye is a 'Factor Release Effect' rather than a Sympathetic Ophthalmic effect which is very rare. Stemedica。 Stemedica discovered the presence of these endogenous RPE stem cells in adult retinas several years ago. This original research demonstrated that these RPE stem cells acquired embryonic markers (Nanog and Oct-4) in adult humans.
目前Stemedica公司正和俄罗斯著名的费奥多罗夫眼科研究所合作进行人体实验治疗RP，我们将密切关注研究的进展，并且将和俄罗斯的研究所取得联系，从而获得最新的相关实验数据。
费奥多罗夫眼科研究所是世界上发明白内障人工晶体植入术的医院。 |
